Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

AT ELANA 841P Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal

A legfontosabb adatok

Ki végzi
Carl Zeiss Meditec, Inc.
Hol
Beverly Hills, Bloomington, Brecksville, Cape Coral, Houston, Hurst, Kenosha, Mt. Pleasant, Northridge, Omaha, Orange, San Antonio, Sioux Falls és St Louis (Egyesült Államok)Mind a 14 helyszín megnézése
Azonosító
Állapot
Befejeződött
Résztvevők
284 fő vett részt
Kezdés
2024. júl. 12.
Befejezés
2025. dec. 1.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Cataract Surgery
A regiszteradat frissítve
2026. augusztus 13.

Ki vehet részt

Életkor
22 év – 100 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 34 feltétel megnézéseKevesebb

Ki vehet részt

  • Adults, 22 years of age or older at the time of study enrollment
  • Bilateral cataractous lens changes as demonstrated by best corrected distance visual acuity of 0.30 logMAR (20/40) or worse either with or without a glare source present (e.g., Brightness Acuity Tester) for which phacoemulsification cataract extraction and posterior chamber IOL implantation is indicated
  • Best corrected distance visual acuity projected to be better than 0.20 logMAR (better than 20/30) after cataract removal and IOL implantation
  • Preoperative keratometric (corneal) astigmatism of 1.00 D or less (≤1.00 D) in both operative eyes
  • Clear intraocular media other than cataract
  • Contact lens wear is to be discontinued two (2) weeks for soft contact lenses both daily and extended wear; and ≥ 30 days for rigid gas permeable lenses prior to preoperative biometry and keratometry testing
  • Calculated lens power within the available range
  • Subject is willing to sign the IRB-approved informed consent form
  • Subject is willing, able and has sufficient cognitive awareness to comply with examination procedures and schedule for follow-up visits

Ki nem vehet részt

  • Previous intraocular or corneal surgery that might confound the outcome of the investigation or increase the risk to the subject, including corneal transplants, retinal detachment, glaucoma surgeries, refractive laser procedures including but not limited to LASIK, limbal relaxing incision, Small Incision Lenticule Extraction (SMILE) etc
  • Currently taking systemic steroids and/or planned on taking systemic steroids prior to operative visit and during the course of the investigation
  • Expected concomitant ocular procedure during cataract surgery or within the next 12 months (e.g., glaucoma surgery including implantation of MIGS, astigmatic correction surgery, penetrating keratoplasty [PK], laser-assisted in situ keratomileusis, SMILE etc.)
  • Concurrent participation in another drug or device investigation that could confound the outcome of this investigation
  • Presence of systemic disease that could increase the operative risk or confound the outcome, including but not limited to diabetes mellitus, active cancer treatment, mental illness, dementia, immunocompromised, connective tissue disease, clinically significant atopic disease, etc
  • Ocular condition that may predispose for future complications, including but not limited to dry eye syndromes or symptoms, anterior segment pathology, glaucoma (uncontrolled despite intake of medication), history of cystoid macular edema, macular degeneration as confirmed by clinical examination and adjunct testing (e.g., OCT, FA)
  • Clinically significant corneal abnormalities, including corneal dystrophy (epithelial, stromal or endothelial dystrophy), irregularity, inflammation or edema; conditions including but not limited to active/inactive keratitis, keratoconjunctivitis, kerato uveitis, keratopathy, keratectasia
  • Use of or history of use of systemic medications with significant ocular side effects or any medications that could confound the outcome or increase subject risk (e.g., Tamsulosin Hydrochloride [Flomax] or other medications including anticholinergics or alpha-adrenergic blocking agents with similar side effects [e.g., small pupil/floppy iris syndrome], antimetabolites, etc.)
  • Subjects with diagnosed degenerative visual disorders, including but not limited to macular degeneration or other retinal disorders (such as diabetic retinopathy, diabetic macular edema, retinal detachment) that are predicted to confound outcomes or to cause future acuity loss to 0.20 logMAR or worse
  • Subjects with conditions that increase the risk of zonular rupture (e.g., pseudoexfoliation syndrome, Marfan's syndrome) during cataract extraction procedure that may affect the postoperative centration or tilt of the IOL
  • History of amblyopia or monofixation syndrome with poor stereoscopic vision
  • History of or current anterior or posterior segment inflammation, including but not limited to iritis or uveitis
  • Pathologic miosis caused by anterior segment pathology in the study eye (e.g., chronic uveitis, iritis, rubeosis iridis, neurological conditions such as multiple sclerosis, Argyle Robertson's pupil, acquired or congenital Horner´s syndrome, etc.)
  • Pregnant, lactating at time of enrollment, or has another condition with associated fluctuation of hormones that could lead to refractive changes
  • Subjects who are expected to require retinal laser treatment within the next 12 months
  • Rubella, congenital, traumatic or complicated cataracts
  • Microphthalmos or macrophthalmos
  • Iris defects (e.g., aniridia)
  • Optic nerve atrophy
  • Keratoconus or Irregular astigmatism, as determined by topography
  • Inability to perform keratometry, topography or biometry (including but not limited to cataract density, subject unable to focus for longer time etc.) or subjects with unstable keratometry, topography or biometry measurements
  • Pupil diameter less than 6 mm when fully dilated
  • Subject whose freedom is impaired by administrative or legal order
  • Subjects unable to achieve keratometry stability after discontinuing contact lens wear
  • Gonioscopic abnormalities

Helyszínek itt: Egyesült Államok

  • Beverly Hills Institute of OphthalmologyBeverly Hills, Egyesült Államok
  • Chu Vision InstituteBloomington, Egyesült Államok
  • Cleveland Eye ClinicBrecksville, Egyesült Államok
  • Cape Coral Eye CenterCape Coral, Egyesült Államok
  • Whitsett Vision GroupHouston, Egyesült Államok
  • Texas Eye & LaserHurst, Egyesült Államok
  • Eye Centers of Racine & KenoshaKenosha, Egyesült Államok
  • Carolina Eyecare Physicians LLCMt. Pleasant, Egyesült Államok
  • Mitchell C Shultz MD/Shultz Chang VisionNorthridge, Egyesült Államok
  • Vance Thompson Vision-NebraskaOmaha, Egyesült Államok
  • Coastal Vision Medical GroupOrange, Egyesült Államok
  • PNV Clinical ResearchSan Antonio, Egyesült Államok
  • Vance Thompson Vision-South DakotaSioux Falls, Egyesült Államok
  • Ophthalmology Consultants of St LouisSt Louis, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this clinical trial is to demonstrate the safety and effectiveness of the full visual range AT ELANA 841P IOL when used to treat adult patients having cataract surgery. Subjects will be randomly selected to receive a pair of IOLs, either the AT ELANA 841P or CT LUCIA 621P lens design. All patients will undergo surgery in both eyes, and they will receive follow up care for up to 6-months. During this time, all patients will undergo thorough eye exams at every study visit and complete questionnaires about their quality of vision post-surgery.

A vizsgálat 2 csoportja

  • AT ELANA 841P IOLA vizsgált kezelés

    Cataract Surgery to implant multifocal intraocular lenses

    Kezelés: Cataract Surgery

  • CT LUCIA 621P IOLMár használt kezelés, összehasonlításként

    Cataract Surgery to implant monofocal intraocular lenses

    Kezelés: Cataract Surgery

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Multi-center, Prospective, Randomized, Controlled Clinical Trial to Demonstrate the Safety and Effectiveness of the Full Visual Range AT ELANA 841P Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal
A regiszteradat frissítve
2026. augusztus 13.